Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1527

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study

Blood Adv (2025) 9 (15): 3865–3877.

https://doi.org/10.1182/bloodadvances.2024014903

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

Blood Adv (2025) 9 (15): 3955–3966.

https://doi.org/10.1182/bloodadvances.2024015719

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Blood Adv (2025) 9 (15): 3665–3675.

https://doi.org/10.1182/bloodadvances.2024015180

Published: 2025

Includes: Supplemental data

Journal Articles

Genetic deregulation of REL in germinal center B cells induces generation of a pool of lymphoma precursor cells

Léa Prévaud, Karima Ferhat, Dilara Sensoy, Ophélie Téteau, Tiffany Marchiol, Quentin Lemasson, Catherine Ouk, Claire Carrion, Michel Cogné, Jean Feuillard, Christelle Vincent-Fabert, Nathalie Faumont

Blood Adv (2025) 9 (15): 3676–3688.

https://doi.org/10.1182/bloodadvances.2023012166

Published: 2025

Includes: Supplemental data

Journal Articles

T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia

Julie Ma, Annie Luong, Andrew Doan, Tsen Yin Lin, Lingyun Ji, Cassandra P. Wang, Seon-Jae Yoon, Teresa Rushing, Anh Duong, Miguel Villa, Chintan Parekh

Blood Adv (2025) 9 (15): 3689–3693.

https://doi.org/10.1182/bloodadvances.2025015894

Published: 2025

Includes: Supplemental data

Journal Articles

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Blood Adv (2025) 9 (15): 3694–3705.

https://doi.org/10.1182/bloodadvances.2024015262

Published: 2025

Includes: Supplemental data

Journal Articles

Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis

Joshua Fieggen, Anshul Thakur, Christopher C. Butler, Karthik Ramasamy, Anjan Thakurta, David A. Clifton, Lei Clifton

Blood Adv (2025) 9 (15): 3766–3770.

https://doi.org/10.1182/bloodadvances.2025016120

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P. Qureshi, Susan M. O’Brien

Blood Adv (2025) 9 (15): 3801–3809.

https://doi.org/10.1182/bloodadvances.2024015417

Published: 2025

Journal Articles

Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism

Axel Künstner, Vera von Kopylow, Philipp Lohneis, Matthias Kümmel, Hanno M. Witte, Lorenz Bastian, Veronica Bernard, Stephanie Stölting, Kathrin Kusch, Nikolas von Bubnoff, Konrad Steinestel, Annette Arndt, Hartmut Merz, Hauke Busch, Alfred C. Feller, Niklas Gebauer

Blood Adv (2025) 9 (15): 3900–3904.

https://doi.org/10.1182/bloodadvances.2025016002

Published: 2025

Includes: Supplemental data

Journal Articles

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Alexey V. Danilov, Swetha Kambhampati Thiruvengadam, Kim Linton, Karen Cumings, Viktor Chirikov, Alex Mutebi, Savreet Bains Chawla, Anindit Chhibber, Fernando Rivas Navarro, Felipe Marques Gonçalves, Anthony Wang, Zhijie Ding, Abualbishr Alshreef, Elena Favaro, Daniela Hoehn, Anna Sureda

Blood Adv (2025) 9 (15): 3754–3765.

https://doi.org/10.1182/bloodadvances.2024015274

Published: 2025

Includes: Supplemental data

Journal Articles

Blinatumomab use in pediatric B-ALL: where are we now?

Anurekha G. Hall, Rachel E. Rau

Blood Adv (2025) 9 (15): 3946–3954.

https://doi.org/10.1182/bloodadvances.2024014043

Published: 2025

Journal Articles

Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis

Yosra M. Aljawai, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Partow Kebriaei, Uday Popat, Betul Oran, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta

Blood Adv (2025) 9 (15): 4023–4036.

https://doi.org/10.1182/bloodadvances.2025016236

Published: 2025

Includes: Supplemental data

Journal Articles

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas

Christina Poh, Jenna M. Voutsinas, Mazyar Shadman, Ryan C. Lynch, Edus H. Warren, Caitlin A. Crimp, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian V. Wu, Michi M. Shinohara, Ajay K. Gopal

Blood Adv (2025) 9 (15): 4037–4042.

https://doi.org/10.1182/bloodadvances.2025016680

Published: 2025

Journal Articles

Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection

Ilske Oschlies, Julia Richter, Amelie Alfert, Fernando Chahud, Stephanie Mueller, Ingrid Simonitsch-Klupp, Hannah von Mersi, Andishe Attarbaschi, Karoline Koch, Christoph Schaefers, Monika Brüggemann, Cecilia Bozzetti, Wilhelm Woessmann, Birgit Burkhardt, Wolfram Klapper

Blood Adv (2025) 9 (15): 3909–3918.

https://doi.org/10.1182/bloodadvances.2025016596

Published: 2025

Includes: Supplemental data

Journal Articles

Routine Prophylaxis with Levetiracetam offers no benefit in CD19 CAR-T for LBCL: a Multicenter Propensity-matched Study

Eugenio Galli, Roberta Di Blasi, Alice Di Rocco, Caterina Cristinelli, Ilaria Pansini, Côme Bommier, Alessandro Corrente, Ilenia De Bernardis, Marcello Viscovo, Stefan Hohaus, Anna Modoni, Federica Sorà, Patrizia Chiusolo, Maurizio Martelli, Simona Sica, Catherine Thieblemont

Blood Adv bloodadvances.2025017378.

https://doi.org/10.1182/bloodadvances.2025017378

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis

Blood Adv bloodadvances.2025016117.

https://doi.org/10.1182/bloodadvances.2025016117

Published: 2025

Includes: Supplemental data

Journal Articles

Mini-Hyper-CVD plus Venetoclax and Navitoclax for Relapsed/Refractory Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop M Kantarjian, Nitin Jain, Tapan M. Kadia, Jayastu Senapati, Fadi G. Haddad, Manuel M Maroun, Koji Sasaki, Lianchun Xiao, Xuelin Huang, Omer Karrar, Regina Abramova, Min Zhao, Rebecca Garris, Marina Y. Konopleva, Farhad Ravandi, Elias Jabbour

Blood Adv bloodadvances.2025016565.

https://doi.org/10.1182/bloodadvances.2025016565

Published: 2025

Includes: Supplemental data

Journal Articles

Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials

Blood Adv bloodadvances.2025016949.

https://doi.org/10.1182/bloodadvances.2025016949

Published: 2025

Includes: Supplemental data

Journal Articles

Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas

Blood Adv bloodadvances.2024015167.

https://doi.org/10.1182/bloodadvances.2024015167

Published: 2025

Includes: Supplemental data

Journal Articles

Monitoring ctDNA in Aggressive B-cell Lymphoma: A Prospective Correlative Study of ctDNA Kinetics and PET-CT Metrics

Gayaththri Vimalathas, Marcus Høy Hansen, Oriane Marie Louise Cédile, Mads Thomassen, Michael Boe Møller, Sara Kamuk Dahlmann, Marie Louise Grube Kjeldsen, Malene Grubbe Hildebrandt, Anne Lerberg Nielsen, Mohammad Naghavi-Behzad, Lars Edenbrandt, Charlotte Guldborg Nyvold, Thomas S. Larsen

Blood Adv bloodadvances.2025016752.

https://doi.org/10.1182/bloodadvances.2025016752

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Genetic deregulation of REL in germinal center B cells induces generation of a pool of lymphoma precursor cells

T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Blinatumomab use in pediatric B-ALL: where are we now?

Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas

Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection

Routine Prophylaxis with Levetiracetam offers no benefit in CD19 CAR-T for LBCL: a Multicenter Propensity-matched Study

Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis

Mini-Hyper-CVD plus Venetoclax and Navitoclax for Relapsed/Refractory Acute Lymphoblastic Leukemia

Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials

Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas

Monitoring ctDNA in Aggressive B-cell Lymphoma: A Prospective Correlative Study of ctDNA Kinetics and PET-CT Metrics

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only